16 results
8-K
EX-99.1
ICAD
Icad Inc
7 May 14
Therapy Revenue Growth of 32% Driven by Continued Adoption of the Xoft System for the Treatment of
12:00am
of 2014 increased to $6.4 million from $6.0 million for the same period in 2013, as a result of higher sales, marketing and R&D expenditures.
Non-GAAP
8-K
EX-99.1
ICAD
Icad Inc
29 Oct 13
Results of Operations and Financial Condition
12:00am
by commercial and R&D investments.
Non-GAAP Adjusted EBITDA: Non-GAAP adjusted EBITDA, a non-GAAP financial measure as defined below, was $545,000
CORRESP
mgy o2aqv
10 Dec 09
Correspondence with SEC
12:00am
8-K
EX-99
g8fzn5cv 8x5wks
24 Feb 04
Regulation FD Disclosure
12:00am
- Prev
- 1
- Next